AMIX
Autonomix MedicalAMIX
AMIX
About: Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
Employees: 8
0
Funds holding %
of 6,814 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
139% more capital invested
Capital invested by funds: $88.9K [Q2] → $212K (+$123K) [Q3]
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
13% more funds holding
Funds holding: 16 [Q2] → 18 (+2) [Q3]
1.11% more ownership
Funds ownership: 0.47% [Q2] → 1.58% (+1.11%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for AMIX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology
Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,064,256 (‘256 patent) titled, Systems and Methods for Treating Cancer and/or Augmenting Organ Function. The issued ‘256 patent covers technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain.
Neutral
GlobeNewsWire
2 weeks ago
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, reflected on the Company's progress made over the last year and shared insight into the year ahead.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount includes the partial exercise of the over-allotment option granted to the underwriter.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses.
Neutral
GlobeNewsWire
2 months ago
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure
Neutral
GlobeNewsWire
2 months ago
Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Access the Virtual Investor “What This Means” Segment here
Positive
Zacks Investment Research
2 months ago
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
Positive
Benzinga
2 months ago
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.
Positive
Benzinga
2 months ago
Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?
Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro.
Charts implemented using Lightweight Charts™